论文部分内容阅读
目的对比替米沙坦与氨氯地平治疗合并2型糖尿病的高血压的临床疗效及其安全性,为此类患者的治疗用药提供参考。方法将2008～2011年期间于本院就诊的80例合并2型糖尿病的高血压患者按照治疗方法不同分为2组,各40例,即替米沙坦组(A组)和氨氯地平组(B组),观察并对比两组患者疗效及其安全性。结果两组患者治疗后收缩压、舒张压、空腹血糖、胰岛素以及胰岛素指数均显著较治疗前降低,另外A组患者治疗后的空腹血糖、胰岛素以及胰岛素指数均显著低于B组。两组患者左心室肥厚各指数均显著降低,但两组间相比差异无统计学意义。两组均未发现明显不良反应,安全性相似。结论替米沙坦是治疗合并2型糖尿病的高血压患者的良好药物选择。
Objective To compare the clinical efficacy and safety of telmisartan and amlodipine in the treatment of type 2 diabetes mellitus with hypertension and to provide references for the treatment of these patients. Methods Eighty patients with type 2 diabetes mellitus who were treated in our hospital from 2008 to 2011 were divided into two groups according to the different treatment methods: 40 cases in each group, namely telmisartan group (A group) and amlodipine group (Group B). The curative effect and safety of the two groups were observed and compared. Results After treatment, the systolic blood pressure, diastolic blood pressure, fasting blood glucose, insulin and insulin index of the two groups were significantly lower than those before treatment. In addition, the fasting blood glucose, insulin and insulin index of patients in group A were significantly lower than those in group B after treatment. The indexes of left ventricular hypertrophy in both groups were significantly decreased, but there was no significant difference between the two groups. No significant adverse reactions were found in both groups with similar safety. Conclusion Telmisartan is a good drug choice for the treatment of hypertensive patients with type 2 diabetes mellitus.